CanSino Biologics Inc.

SHSC:6185 Stock Report

Market Cap: HK$11.3b

CanSino Biologics Management

Management criteria checks 4/4

CanSino Biologics' CEO is Xuefeng Yu, appointed in Jan 2009, has a tenure of 15.92 years. total yearly compensation is CN¥3.97M, comprised of 64.1% salary and 35.9% bonuses, including company stock and options. directly owns 7.28% of the company’s shares, worth HK$818.67M. The average tenure of the management team and the board of directors is 6.8 years and 3.2 years respectively.

Key information

Xuefeng Yu

Chief executive officer

CN¥4.0m

Total compensation

CEO salary percentage64.1%
CEO tenure15.9yrs
CEO ownership7.3%
Management average tenure6.8yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Xuefeng Yu's remuneration changed compared to CanSino Biologics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CN¥720m

Jun 30 2024n/an/a

-CN¥867m

Mar 31 2024n/an/a

-CN¥2b

Dec 31 2023CN¥4mCN¥3m

-CN¥1b

Sep 30 2023n/an/a

-CN¥1b

Jun 30 2023n/an/a

-CN¥2b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥5mCN¥2m

-CN¥909m

Compensation vs Market: Xuefeng's total compensation ($USD543.29K) is about average for companies of similar size in the Hong Kong market ($USD459.37K).

Compensation vs Earnings: Xuefeng's compensation has been consistent with company performance over the past year.

CEO

Xuefeng Yu (59 yo)

15.9yrs

Tenure

CN¥3,965,000

Compensation

Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...

Leadership Team

NamePositionTenureCompensationOwnership
Xuefeng Yu
Co-Founder15.9yrsCN¥3.97m7.28%
HK$ 818.7m
Tao Zhu
Co-Founder15.9yrsCN¥4.42m7.27%
HK$ 818.1m
Dongxu Qiu
Co-Founder15.9yrsCN¥3.74m6.94%
HK$ 780.4m
Shou-Bai Chao
COO, Deputy GM & Executive Director6.6yrsCN¥3.93m0.028%
HK$ 3.1m
Jing Wang
Chief Commercial Officer3.3yrsCN¥4.57m0.0072%
HK$ 811.3k
Chunlin Xin
Senior Director of New Technology Department7.1yrsno datano data
Yonghui Wu
Vice President of Marketingno datano datano data
Jin Cui
Board Secretary5.8yrsno datano data
Ming King Chiu
Joint Company Secretary5.8yrsno datano data

6.8yrs

Average Tenure

51yo

Average Age

Experienced Management: 6185's management team is seasoned and experienced (6.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Xuefeng Yu
Co-Founder15.9yrsCN¥3.97m7.28%
HK$ 818.7m
Shou-Bai Chao
COO, Deputy GM & Executive Director6.5yrsCN¥3.93m0.028%
HK$ 3.1m
Jing Wang
Chief Commercial Officer3.2yrsCN¥4.57m0.0072%
HK$ 811.3k
George R. Siber
Co-Chair of Scientific Advisory Board1.9yrsno datano data
Shan Lu
Member of the Scientific Advisory Board2.6yrsno datano data
Shuifa Gui
Independent Non-Executive Director5.1yrsCN¥300.00kno data
Luis Barreto
Member of Scientific Advisory Boardno datano datano data
Zhi Xiao
Chairman of Employee Representative Supervisorless than a yearno datano data
Jianzhong Liu
Independent Non-Executive Director5.1yrsCN¥300.00k0.00040%
HK$ 45.0k
Liming Li
Co-Chair of Scientific Advisory Board1.9yrsno datano data
Jingren Zhang
Member of Scientific Advisory Boardno datano datano data
Leung Cheung Yiu
Independent Non-Executive Directorno datano datano data

3.2yrs

Average Tenure

59yo

Average Age

Experienced Board: 6185's board of directors are considered experienced (3.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 21:09
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CanSino Biologics Inc. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Lijian ZhaoChina International Capital Corporation Limited
Hangci ZhengChina International Capital Corporation Limited